Dewpoint Launches Promising Cancer Trial for Solid Tumors
Dewpoint Therapeutics has dosed the first patient in a Phase 1a/2a study of DPTX3186, a first-in-class small molecule that...
Jon Napitupulu
Adial Applauds New Path for Substance Use Disorder Trials
Congress’s 2026 appropriations package for HHS embeds a clear directive: FDA and NIDA are to collaborate on alternative clinical...
Pivotal DEVOTE Study Results on High-Dose Nusinersen in SMA
Treatment-naïve infants with SMA receiving Biogen’s higher-dose nusinersen regimen achieved a 26.19-point advantage on CHOP-INTEND versus a prespecified matched...
First Patient Enrolled in Japan Prostate Cancer Trial
Global Phase 3 data for 177Lu‑PSMA‑I&T have met the primary endpoint with statistically significant, clinically meaningful benefit in metastatic...
BioStem Aligns with FDA’s Bayesian Clinical Trial Approach
In a randomized study of diabetic foot ulcers, BioStem’s BioRetain-processed allografts were reported to be nearly twice as likely...
Neomorph Doses First Patient in NEO-811 Cancer Trial
Neomorph has opened dosing in its first-in-human Phase 1/2 study of NEO-811, an oral, cereblon-dependent molecular glue degrader being...
Theriva to Present VCN-01 Retinoblastoma Trial Data at APAO
Theriva Biologics will present safety and clinical outcomes from an investigator-sponsored Phase 1 study of intravitreal VCN-01 (zabilugene almadenorepvec)...
BioCardia to Present Late-Breaking CardiAMP HF Trial Data
No efficacy or safety numbers were disclosed. BioCardia’s CardiAMP autologous cell therapy will be featured as a Late Breaking...
Arcutis’ Zoryve Cream: A Promising Trial for Infant Eczema
Fifty-eight percent of infants treated with roflumilast cream 0.05% achieved EASI-75 at Week 4 in an open-label Phase 2...
Successful Milestone for Actinogen’s Alzheimer’s Trial
An independent Data Monitoring Committee reviewed unblinded interim data from approximately 37% of Actinogen’s pivotal XanaMIA Alzheimer’s disease trial...